| TBCRC 018 | TBCRC 018: A Phase II Study of the PARP Inhibitor, BSI-201, in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis | View Details |
| TBCRC 017 | TBCRC 017: Retrospective Project for the Predictive Accuracy of MRI to Determine Pathological Status in Patients Treated with Neoadjuvant Chemotherapy (NCT). | View Details |
| TBCRC 011 | TBCRC 011: A Non-randomized, Single Agent, Open-label, Phase II Study of Bicalutamide in Patients with AR+, ER-/PR- Metastatic Breast Cancer (MBC) | View Details |
| TBCRC 008 | TBCRC 008: A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Measurable Outcome to Carboplatin and nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer | View Details |
| TBCRC 007 | TBCRC 007: A Phase II comparison and effectiveness study of medroxyprogesterone acetate (MPA) alone or in combination with low-dose chemotherapy in postmenopausal women with hormone receptor negative (HR-), metastatic breast cancer (MBC) | View Details |
| TBCRC 001 | TBCRC 001: Comparison and effectiveness of cetuximab alone or cetuximab with carboplatin in women with triple negative, metastatic breast cancer (MBC) | View Details |